We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 1.11% for the day. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, lost 1.89%.
Shares of the company have depreciated by 14.87% over the course of the past month, underperforming the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. It is anticipated that the company will report an EPS of -$1.20, marking a 209.09% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.83 million, indicating a 94.62% decrease compared to the same quarter of the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.75% higher. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 66, positioning it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 1.11% for the day. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, lost 1.89%.
Shares of the company have depreciated by 14.87% over the course of the past month, underperforming the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. It is anticipated that the company will report an EPS of -$1.20, marking a 209.09% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.83 million, indicating a 94.62% decrease compared to the same quarter of the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.75% higher. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 66, positioning it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.